Introduction to Familial Hypocalciuric Hypercalcemia (FHH)
Familial hypocalciuric hypercalcemia (FHH) is a genetic disorder distinguished by mild hypercalcemia, typically observed in individuals who are otherwise healthy and asymptomatic. Often discovered during routine serum chemistry panels, hypercalcemia is a frequent reason for medical consultation and further investigation. The diagnostic process for hypercalcemia usually depends on the presentation’s acuity and severity, as well as the concurrent levels of serum parathyroid hormone (PTH). FHH arises from mutations in the calcium-sensing receptor gene (CASR), which lead to diminished receptor activity in response to serum calcium concentrations. This genetic alteration results in a characteristic biochemical profile of mild hypercalcemia, hypocalciuria, hypermagnesemia, and hypophosphatemia, alongside normal to slightly elevated serum PTH levels.
FHH is generally a benign condition without the severe long-term consequences often associated with other hypercalcemic syndromes. The defining characteristic of FHH is an altered calcium-sensing mechanism. This alteration renders the parathyroid glands less sensitive to calcium, necessitating a higher serum calcium level to effectively suppress PTH release. Consequently, there is increased reabsorption of calcium and magnesium in the kidneys. Accurate Fhh Diagnosis is crucial to differentiate it from other conditions, especially primary hyperparathyroidism (PHPT), to ensure appropriate patient management and prevent unnecessary interventions.
Unpacking the Etiology of FHH: Genetic Basis and Types
The CASR gene is pivotal in maintaining calcium homeostasis. It plays a crucial role in regulating PTH secretion to keep ionized calcium in the blood at a physiological level. In the majority of cases, familial hypocalciuric hypercalcemia (FHH) type 1 is the result of a loss-of-function, heterozygous mutation in the CASR gene located on the long arm of chromosome 3. Individuals with a homozygous mutation can experience severe hypercalcemia coupled with marked neonatal hyperparathyroidism, bone fractures, and failure to thrive.
Rarer forms of familial hypocalciuric hypercalcemia, including FHH type 2 and FHH type 3, have been linked to mutations on chromosome 19. More recent genetic research has identified associations between loss-of-function mutations on the GNA11 gene and missense mutations in the AP2S1 gene with FHH type 2 and FHH type 3, respectively. In very rare instances, FHH can be caused by autoantibodies directed against the calcium-sensing receptor, leading to decreased CASR activity. This autoimmune etiology should be considered in patients with a strong family history of autoimmune disorders and when other causes for clinical findings have been ruled out. Understanding these genetic underpinnings is fundamental for accurate fhh diagnosis and genetic counseling.
Epidemiology of Familial Hypocalciuric Hypercalcemia
FHH is considered a rare disease, inherited in an autosomal dominant pattern, affecting both sexes equally. Estimates suggest that FHH is present in approximately 1 in 10,000 to 100,000 individuals. However, the true prevalence may be higher than reported. This is largely due to its often subclinical nature and the diagnostic challenges in distinguishing FHH from PHPT. Population-based studies and enhanced genetic screening are increasingly important to gain a more precise understanding of FHH epidemiology and improve fhh diagnosis rates.
Pathophysiology of FHH: How Calcium Sensing Goes Awry
CASR-expressing tissues are widespread throughout the body, including the parathyroid glands, kidneys, bone, thyroidal C cells, and enterocytes. In the parathyroid gland’s chief cells, CASR plays a critical role in controlling the synthesis and release of PTH. The CASR is also expressed across all nephron segments in the kidney and influences calcium reabsorption. PTH is released by the parathyroid gland in response to decreased ionized calcium levels, leading to increased tubular calcium reabsorption. Conversely, hypercalcemia suppresses PTH release and promotes urinary excretion of calcium, sodium chloride, and magnesium, independent of PTH and calcitonin levels.
In FHH, loss-of-function mutations in the CASR gene in the parathyroid gland elevate the set point for calcium sensing. This reduced sensitivity means the parathyroid glands require a higher-than-normal serum calcium level to effectively reduce PTH release. In the kidneys, this defect leads to increased tubular reabsorption of both calcium and magnesium. The result is the characteristic triad of hypercalcemia, hypocalciuria, and frequently high-normal levels of serum magnesium. Comprehending this pathophysiology is crucial for clinicians aiming for an accurate fhh diagnosis and appropriate management strategies.
History and Physical Examination in FHH Diagnosis
Most individuals with FHH type 1 are asymptomatic or exhibit very few symptoms associated with mild hypercalcemia. When symptoms do occur, they are often nonspecific. Patients may report fatigue, weakness, constipation, polyuria, polydipsia, or headaches. It is worth noting that patients with FHH type 3 tend to be more symptomatic and can even present with hypophosphatemia and osteomalacia in some cases.
Typically, FHH type 1 is not associated with an increased incidence of fractures. However, fractures and osteoporosis can still occur in these patients. Intrauterine bone abnormalities within the same family, as well as chondrocalcinosis, have been reported in the literature. While some reports have linked FHH to pancreatitis, a causal relationship has not been definitively established. There are also case reports of children with FHH presenting with nephrotic syndrome. A thorough history and physical examination, though often yielding subtle findings in FHH, remains an important initial step in the fhh diagnosis process.
Diagnostic Evaluation: Confirming FHH Diagnosis
Diagnosing FHH can be challenging because the clinical features of FHH and PHPT can overlap significantly. However, differentiating between these two conditions is critical for appropriate management. The initial step in evaluating for FHH involves obtaining a comprehensive clinical history, including a detailed family medical history. Reviewing previous medical records for documented hypercalcemia in serum laboratory testing is essential to establish chronicity and can provide valuable clues, as asymptomatic hypercalcemia detected before the age of 40 often suggests FHH.
Clinical indicators suggestive of FHH include the absence of typical hypercalcemic symptoms, mildly elevated calcium levels alongside an “inappropriately” normal or mildly elevated PTH level, a family history of hypercalcemia, or a personal or family history of unsuccessful neck exploration for hyperparathyroidism. However, it is important to note that some patients with FHH can present with frank hypercalcemia and elevated PTH levels, further complicating fhh diagnosis.
A crucial diagnostic tool in differentiating FHH from PHPT is the measurement of 24-hour urine calcium excretion. Low urinary calcium excretion is a hallmark of FHH. The calcium clearance to creatinine clearance ratio (Ca/Cr excretion ratio) is also widely used to distinguish between FHH and PHPT. A very low Ca/Cr ratio (typically <0.01) strongly suggests FHH. While a low Ca/Cr ratio is highly indicative of FHH, it is important to note that approximately 10% of sporadic PHPT cases can also exhibit a Ca/Cr ratio of <0.01. Genetic testing for CASR mutations is increasingly recommended, especially in patients with a calcium/creatinine clearance ratio of ≤0.020, to definitively confirm fhh diagnosis.
Differentiation between FHH and PHPT becomes even more complex in the absence of a clear family history, when PTH levels are within the normal range, or if the Ca/Cr clearance ratio falls in the intermediate range (>0.01 but <0.02). Although the age at which hypercalcemia is diagnosed and family history are important guiding factors, de novo mutations occur in approximately 15% of FHH cases. Therefore, the absence of family history does not exclude the diagnosis of FHH.
It is essential to exclude and correct other potential causes of hypocalciuria before urinary calcium assessment. Conditions such as vitamin D deficiency, extremely low calcium intake, renal disease, and the use of thiazide diuretics or lithium can artificially lower urinary calcium levels. Serum magnesium levels can also aid in differential fhh diagnosis; patients with FHH often have serum magnesium levels in the upper-normal range or mildly elevated, while PHPT is typically associated with low magnesium levels.
Treatment and Management Strategies for FHH
Since FHH is generally a benign disorder and most patients do not develop significant complications, patient education and reassurance are paramount and often sufficient for managing FHH. Educating affected family members is equally important. In rare cases with atypical features or complications, a sub-total parathyroidectomy may be considered, although this is not a standard treatment for typical FHH.
The calcium-sensing receptor (CASR) itself represents a potential therapeutic target, particularly in more symptomatic cases. Calcimimetic medications, such as Cinacalcet-HCL, have been used successfully in both adults and children to stimulate the CASR. This stimulation can mitigate and sometimes resolve hypercalcemia associated with FHH. Bisphosphonates have also been used to manage hypercalcemia in FHH; however, given the chronic nature of FHH, they would likely require repetitive dosing. Clinicians should be aware that while these therapies are used off-label, the Food and Drug Administration (FDA) has not officially approved them for the treatment of FHH. The primary goal of management is to ensure accurate fhh diagnosis and avoid unnecessary interventions, focusing on patient well-being and education.
Differential Diagnosis: Distinguishing FHH from Similar Conditions
FHH must be carefully differentiated from other causes of PTH-dependent hypercalcemia, especially primary hyperparathyroidism (PHPT). Both PHPT and FHH present with elevated serum calcium levels and either inappropriately normal or high serum parathyroid levels. However, PHPT tends to exhibit higher calcium and PTH levels compared to FHH. PHPT is typically associated with increased urinary calcium, low serum phosphorus, and low magnesium levels. Untreated PHPT carries a significant risk of complications, including constipation, dehydration, nephrolithiasis, chronic kidney disease, and secondary osteoporosis with fractures.
Differentiating FHH can also be challenging from other conditions that present with low urinary calcium, although some of these might not typically involve high serum calcium levels. Poor oral calcium intake and vitamin D deficiency can lead to low urine calcium and compensatory secondary hyperparathyroidism. Thiazide diuretics can decrease renal calcium excretion and potentially cause mild hypercalcemia, which may sometimes unmask underlying FHH or mild PHPT. However, in individuals without FHH or PHPT, thiazide-induced hypercalcemia typically suppresses PTH levels.
Chronic kidney disease (CKD) presents a unique diagnostic challenge. CKD can be associated with high PTH levels, high calcium levels, and low urinary calcium, particularly if tertiary hyperparathyroidism develops or if iatrogenic hypercalcemia occurs during the treatment of secondary hyperparathyroidism. A meticulous approach to differential fhh diagnosis is essential to avoid misdiagnosis and ensure appropriate patient care.
Prognosis of Familial Hypocalciuric Hypercalcemia
In most cases, FHH follows a benign disease course and carries a favorable prognosis with no associated long-term adverse effects, unlike some other hypercalcemia syndromes. This benign prognosis underscores the importance of accurate fhh diagnosis to prevent unnecessary and potentially harmful treatments like parathyroidectomy, which is indicated for PHPT but not for typical FHH.
Complications Associated with FHH
In rare instances of homozygous mutations, FHH can manifest as severe neonatal hyperparathyroidism. Typically, homozygous FHH presents within the first six months of life and exhibits features more characteristic of severe PTH-mediated hypercalcemia than typical FHH. Extremely high calcium levels can lead to dehydration due to polyuria. Other symptoms in neonates can include hypotonia, failure to thrive, and bone changes, which may be further complicated by fractures. Fetal intrauterine bone abnormalities have also been reported in affected families.
In adults, complications from hypercalcemia are less common in typical FHH but can occur, especially when serum calcium levels are moderately to severely elevated (serum calcium >12 mg/dL). Documented complications in adults include fractures, chondrocalcinosis, nephrolithiasis, arrhythmias, and, rarely, pancreatitis. Recognizing these potential complications is important for comprehensive patient management following fhh diagnosis.
Deterrence and Patient Education for FHH
FHH is a rare genetic condition that results in elevated calcium levels in the blood. The calcium-sensing receptor in individuals with FHH requires higher than normal calcium levels to stimulate the parathyroid glands to regulate calcium levels effectively. FHH is generally a benign condition and, in most cases, is not associated with symptoms or the typical complications seen with prolonged hypercalcemia. However, in rare instances, especially in newborns and infants, complications from high calcium levels can occur. Medical treatment or surgery to remove the parathyroid glands might be necessary in patients who develop complications, although surgery is generally not indicated for typical FHH.
Due to its genetic nature, multiple family members can be affected by FHH. Therefore, clinical evaluation of blood relatives is recommended when a patient receives an fhh diagnosis. Clinicians should thoroughly discuss abnormal calcium levels with patients and their families and exclude more common causes of hypercalcemia as clinically indicated. Genetic counseling should be offered to families affected by FHH to understand the inheritance pattern and recurrence risk.
Clinical Pearls and Key Considerations in FHH
In general, FHH is a non-progressive, benign disorder rarely associated with complications. Calcium and PTH levels typically remain stable over time. Distinguishing asymptomatic PHPT from FHH is crucial because parathyroidectomy, the definitive treatment for PHPT, will not cure FHH and is contraindicated in typical cases. Differentiating patients with atypical presentations of either disease, particularly in the absence of a family history, can be more challenging. Family screening and education are imperative to avoid unnecessary procedures for family members who may also have FHH. Accurate fhh diagnosis relies on a combination of clinical history, biochemical testing, and, in some cases, genetic confirmation.
Enhancing Healthcare Team Outcomes in FHH Management
Patients with hypercalcemia are frequently encountered by nurse practitioners, primary care clinicians, and internists, often triggered by a family member’s diagnosis prompting further evaluation. Healthcare professionals should be knowledgeable about FHH to minimize unnecessary tests and procedures. An interprofessional approach is essential for optimal patient care. Endocrinologists should be consulted for atypical presentations or diagnostic dilemmas. In very rare instances where parathyroidectomy is considered for complications, surgeons are involved. Pharmacists play a vital role in managing medications such as calcimimetic agents or bisphosphonates when used in severe cases. Geneticists should evaluate patients and their families to confirm the fhh diagnosis and provide genetic counseling. Pediatricians should assess affected children. Effective interprofessional communication and care coordination are crucial to enhance patient-centered care, improve outcomes, ensure patient safety, and optimize team performance by avoiding redundant and costly monitoring and interventions.
Review Questions
(Note: Review questions are present in the original article but are not typically included in SEO-optimized educational content. They are omitted here to maintain focus on informational content.)
References
1.Law WM, Heath H. Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families. Ann Intern Med. 1985 Apr;102(4):511-9. [PubMed: 3977197]
2.Lee JY, Shoback DM. Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):609-619. [PMC free article: PMC6767927] [PubMed: 30449544]
3.Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci. 2005;42(1):35-70. [PubMed: 15697170]
4.Pearce SH, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, Heath DA, Hughes IA, Paterson CR, Whyte MP. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest. 1995 Dec;96(6):2683-92. [PMC free article: PMC185975] [PubMed: 8675635]
5.Heath H, Jackson CE, Otterud B, Leppert MF. Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity. Am J Hum Genet. 1993 Jul;53(1):193-200. [PMC free article: PMC1682230] [PubMed: 8317484]
6.Lloyd SE, Pannett AA, Dixon PH, Whyte MP, Thakker RV. Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am J Hum Genet. 1999 Jan;64(1):189-95. [PMC free article: PMC1377717] [PubMed: 9915958]
7.Michigami T. [Disorders Caused by Mutations in Calcium-Sensing Receptor and Related Diseases.]. Clin Calcium. 2017;27(4):521-527. [PubMed: 28336828]
8.Szalat A, Shpitzen S, Tsur A, Zalmon Koren I, Shilo S, Tripto-Shkolnik L, Durst R, Leitersdorf E, Meiner V. Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia. Endocrine. 2017 Mar;55(3):741-747. [PubMed: 28176280]
9.Pallais JC, Kemp EH, Bergwitz C, Kantham L, Slovik DM, Weetman AP, Brown EM. Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor. J Clin Endocrinol Metab. 2011 Mar;96(3):672-80. [PMC free article: PMC3047232] [PubMed: 21159843]
10.Riccardi D, Brown EM. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol. 2010 Mar;298(3):F485-99. [PMC free article: PMC2838589] [PubMed: 19923405]
11.Chanpaisaeng K, Teerapornpuntakit J, Wongdee K, Charoenphandhu N. Emerging roles of calcium-sensing receptor in the local regulation of intestinal transport of ions and calcium. Am J Physiol Cell Physiol. 2021 Mar 01;320(3):C270-C278. [PubMed: 33356945]
12.Krupinova JA, Almaskhanova AA, Eremkina AK, Bibik EE, Vasilyev EV, Mokrysheva NG. [A series of clinical cases of familial hypocalciuric hypercalcemia syndrome]. Probl Endokrinol (Mosk). 2020 Oct 31;66(5):61-69. [PubMed: 33369373]
13.Mohammed R, Bray MB, Koch CA, Uwaifo GI. Spontaneous rib fractures in a black woman with familial hypocalciuric hypercalcemia. Med Sci Monit. 2008 Oct;14(10):CS102-6. [PubMed: 18830196]
14.Frerot A, Baudouin V, Rideau-Batista A, Couderc A, Garel C, Soltane S, Colella M, Vargas-Poussou R, Hureaux M. Prenatal bone abnormalities in three cases of familial hypocalciuric hypercalcemia. Prenat Diagn. 2022 May;42(5):583-588. [PubMed: 35301736]
15.Volpe A, Guerriero A, Marchetta A, Caramaschi P, Furlani L. Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis. Joint Bone Spine. 2009 Dec;76(6):708-10. [PubMed: 19467900]
16.Alix L, Guggenbuhl P. Familial hypocalciuric hypercalcemia associated with crystal deposition disease. Joint Bone Spine. 2015 Jan;82(1):60-2. [PubMed: 25444087]
17.Davies M, Klimiuk PS, Adams PH, Lumb GA, Large DM, Anderson DC. Familial hypocalciuric hypercalcaemia and acute pancreatitis. Br Med J (Clin Res Ed). 1981 Mar 28;282(6269):1023-5. [PMC free article: PMC1504882] [PubMed: 6783229]
18.Stuckey BG, Gutteridge DH, Kent GN, Reed WD. Familial hypocalciuric hypercalcaemia and pancreatitis: no causal link proven. Aust N Z J Med. 1990 Oct;20(5):718-9, 725. [PubMed: 2285390]
19.Yu M, Xue M, Fan X, Gao C, Xia Z. Nephrotic Syndrome Complicated with Familial Hypocalciuric Hypercalcemia in an Infant: A Case Report and Comprehensive Literature Review. Altern Ther Health Med. 2024 May 03; [PubMed: 38702153]
20.Heath H. Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. Endocrinol Metab Clin North Am. 1989 Sep;18(3):723-40. [PubMed: 2673770]
21.Zajíčková K, Dvořáková M, Moravcová J, Včelák J, Goltzman D. Familial hypocalciuric hypercalcemia in an index male: grey zones of the differential diagnosis from primary hyperparathyroidism in a 13-year clinical follow up. Physiol Res. 2020 Sep 30;69(Suppl 2):S321-S328. [PMC free article: PMC8603734] [PubMed: 33094630]
22.Cetani F, Dinoi E, Pierotti L, Pardi E. Familial states of primary hyperparathyroidism: an update. J Endocrinol Invest. 2024 Sep;47(9):2157-2176. [PubMed: 38635114]
23.Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf). 2008 Nov;69(5):713-20. [PubMed: 18410554]
24.Ghaznavi SA, Saad NM, Donovan LE. The Biochemical Profile of Familial Hypocalciuric Hypercalcemia and Primary Hyperparathyroidism during Pregnancy and Lactation: Two Case Reports and Review of the Literature. Case Rep Endocrinol. 2016;2016:2725486. [PMC free article: PMC5120212] [PubMed: 27957351]
25.Koca SB. Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature. Turk J Pediatr. 2023;65(5):853-861. [PubMed: 37853976]
26.Palumbo VD, Palumbo VD, Damiano G, Messina M, Fazzotta S, Lo Monte G, Lo Monte AI. Tertiary hyperparathyroidism: a review. Clin Ter. 2021 May 05;172(3):241-246. [PubMed: 33956045]
27.Liu J, Tio MC, Verma A, Schmidt IM, Ilori TO, Knauf F, Mc Causland FR, Waikar SS. Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease. J Clin Endocrinol Metab. 2022 Jan 01;107(1):e281-e292. [PMC free article: PMC8684460] [PubMed: 34390334]
